1 in 4 Black men will get prostate cancer in their lifetime. Black men are more likely to get prostate cancer than other men, who have a 1 in 8 chance of getting prostate cancer. We don’t know why, but it might be linked to genes. We're funding research to find out why Black men are at higher risk of prostate cancer than other men.

You may also be more likely to get prostate cancer as a Black man if:

  • you are aged 45 or over – and your risk increases as you get older
  • your father or brother has had it
  • your mother or sister has had breast cancer.
Publications Booklet Stickman (1)

Prostate cancer and other prostate problems

Information for Black men. This leaflet explains about prostate cancer and other prostate problems, including who is at risk and what changes to look out for.

Download or order leaflet

I’m a Black man over 45. What should I do next?

If you’re Black, have a prostate and you’re over 45, speak to your GP about your risk of prostate cancer. We also strongly recommend you speak to them about having a PSA test (a blood test that can help diagnose prostate cancer).

There are advantages and disadvantages to having a PSA test. You’ll need to talk to your GP or practice nurse about these before deciding whether to have one. Remember to tell them if anyone in your family has had prostate cancer or breast cancer.

You can also get in touch with our Specialist Nurses, who can help you understand your risk of prostate cancer. You may find it helpful to take our 30 second risk checker.

Why would I go to my GP if I don’t have any symptoms?

Most men with early prostate cancer (cancer that’s contained inside the prostate) don’t have any symptoms. 

Symptoms usually develop if the cancer grows near and presses against the tube you urinate through, changing the way you urinate (wee). But because prostate cancer usually starts to grow in a different part (usually the outer part) of the prostate, early prostate cancer doesn’t often press on the urethra and cause symptoms.

If prostate cancer breaks out of the prostate (locally advanced prostate cancer) or spreads to other parts of the body (advanced prostate cancer), it can cause other symptoms.

If you do have prostate cancer and it’s caught early before it causes symptoms, there’s a good chance treatment could stop the cancer spreading. It may not be possible to cure your cancer but you may be able to have treatment to help control the cancer and manage symptoms.

What will happen if I go to my GP?

Your GP will talk to you about your risk of prostate cancer and the tests you can have to diagnose it. There are a few tests that can find out whether you might have prostate cancer or another prostate problem, such as an enlarged prostate or prostatitis

Your GP will talk to you about your test results and what they mean.  If they think you may have a prostate problem, they may make an appointment for you to see a specialist at the hospital. There are advantages and disadvantages of having tests for prostate cancer. Talk to your doctor or nurse about these.

It’s natural to feel worried or embarrassed about going to the doctor or having tests. But don’t let that stop you going to your GP. Remember, the tests give your GP the best idea about whether you have a problem that needs treating.  

If you’re not sure about what to say to your GP, print and fill out this form and show it to them. This will help you have the conversation.

Read more about tests or download our leaflet Prostate cancer and other prostate problems: Information for black men. You can also speak to our Specialist Nurses about what to expect at a GP appointment.

What can I do if my doctor won't give me a PSA blood test?

If you’re a Black man over 50, you have the right to a PSA test if you've thought carefully about the advantages and disadvantages

If your GP doesn't agree to give you a PSA test, you can ask to see another GP or practice nurse, or make a complaint. Read more about what you can do.

If you’re a Black man aged 45-49, you aren’t entitled to a PSA test until you’re 50. But, because you’re at higher risk, many health professionals believe that you should be able to have tests from the age of 45 if you've thought about the advantages and disadvantages. We have guidelines for health professionals that explain this. It might help to show these to your GP or practice nurse. Or ask to see another GP or practice nurse.

If you’re a Black man aged 40-44, you aren’t entitled to a PSA test until you’re 50. But some health professionals believe that you should think about asking for a baseline PSA test. This might help to work out your risk of getting prostate cancer in future. We have guidelines for health professionals that explain this. It might help to show these to your GP or practice nurse. Or ask to see another GP or practice nurse.

If you’re a Black man under 40, you could consider asking for a baseline test when you are 40.

I’m a Black man under 45. What can I do?

When you’re 45, speak to your GP about your risk of prostate cancer.

If you’re aged 40-44, you could think about asking for a PSA test to help work out your risk of getting prostate cancer in the future. The aim of a baseline test is not to help diagnose prostate cancer, but to help work out your risk of getting prostate cancer in the future.

There is some research suggesting that your PSA level in your 40s could be used to predict how likely you are to get prostate cancer, or fast-growing (aggressive) prostate cancer, later in life. If the test suggests you’re at higher risk, you and your doctor may decide to do regular PSA tests. This might be a good way to spot any changes in your PSA level that might suggest prostate cancer.

However, we don’t yet know exactly what PSA level in your 40s would show an increased risk of prostate cancer, or how often you should have more tests. Because of this, baseline testing isn’t very common in the UK.

Your GP doesn’t have to give you a baseline PSA test. If your GP won’t give you a test, read about what you can do.


Updated: January 2023|To be reviewed: January 2025

  • Aaron L, Franco O, Hayward S. Review of Prostate Anatomy and Embryology and the Etiology of BPH. Urol Clin North Am. 2016 Aug;43(3):279–88.
  • Allott EH, Masko EM, Freedland SJ. Obesity and Prostate Cancer: Weighing the Evidence. Eur Urol. 2013 May;63(5):800–9.
  • Ballon-Landa E, Parsons JK. Nutrition, physical activity, and lifestyle factors in prostate cancer prevention. Curr Opin Urol. 2017 Oct 18;
  • Barber L, Gerke T, Markt SC, Peisch SF, Wilson KM, Ahearn T, et al. Family History of Breast or Prostate Cancer and Prostate Cancer Risk. Clin Cancer Res. 2018 Dec 1;24(23):5910–7.
  • Ben-Shlomo Y, Evans S, Ibrahim F, Patel B, Anson K, Chinegwundoh F, et al. The Risk of Prostate Cancer amongst Black Men in the United Kingdom: The PROCESS Cohort Study. Eur Urol. 2008 Jan;53(1):99–105.
  • Acute prostatitis - Symptoms, diagnosis and treatment | BMJ Best Practice [Internet]. 2018 [cited 2019 Jan 4]. Available from: https://bestpractice.bmj.com/topics/en-gb/172?q=Prostatitis&c=suggested
  • Bonkat G, Bartoletti R, Bruyère F, Cai T, Geerlings SE, Koves B, et al. EAU Guidelines on Urological infections [Internet]. European Association of Urology; 2020 [cited 2020 Dec 1]. Available from: https://uroweb.org/wp-content/uploads/EAU-Guidelines-on-Urological-infections-2020.pdf
  • Brede CM, Shoskes DA. The etiology and management of acute prostatitis. Nat Rev Urol. 2011 Apr;8(4):207–12.
  • Cancer Research UK. Prostate cancer incidence statistics (2015-2017) [Internet]. 2017 [cited 2020 Nov 27]. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer/incidence#heading-Zero
  • Cancer Research UK. Prostate cancer incidence statistics: by age (2015-2017) [Internet]. 2017 [cited 2020 Nov 27]. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer/incidence
  • Coker TJ, Dierfeldt DM. Acute Bacterial Prostatitis: Diagnosis and Management. Am Fam Physician. 2016 Jan 15;93(2):114–20.
  • Das H, Rodriguez R. Health Care Disparities in Urologic Oncology: A Systematic Review. Urology. 2020 Feb;136:9–18.
  • Discacciati A, Orsini N, Wolk A. Body mass index and incidence of localized and advanced prostate cancer--a dose-response meta-analysis of prospective studies. Ann Oncol. 2012 Jan 6;23(7):1665–71.
  • Ellent E, Matrana MR. Metastatic Prostate Cancer 35 Years After Sex Reassignment Surgery. Clin Genitourin Cancer. 2016 Apr 1;14(2):e207–9.
  • Gooren L, Morgentaler A. Prostate cancer incidence in orchidectomised male-to-female transsexual persons treated with oestrogens. Andrologia. 2014 Dec;46(10):1156–60.
  • Gravas S, Cornu JN, Gacci M, Gratzke C, Herrmann TRW, Mamoulakis C, et al. EAU Guidelines on Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO) [Internet]. European Association of Urology; 2020 [cited 2020 Nov 26]. Available from: https://uroweb.org/wp-content/uploads/EAU-Guidelines-on-Non-Neurogenic-Male-LUTS-incl.-BPO-2020.pdf
  • Jarvis TR, Chughtai B, Kaplan SA. Bladder Outlet Obstruction and BPH. Curr Bladder Dysfunct Rep. 2014 Dec;9(4):372–8.
  • Jones AL, Chinegwundoh F. Update on prostate cancer in black men within the UK. Ecancermedicalscience. 2014;8:455.
  • Kiciński M, Vangronsveld J, Nawrot TS. An Epidemiological Reappraisal of the Familial Aggregation of Prostate Cancer: A Meta-Analysis. PLoS ONE. 2011 Oct 31;6(10):e27130.
  • Lamy PJ, Trétarre B, Rebillard X, Sanchez M, Cénée S, Ménégaux F. Family history of breast cancer increases the risk of prostate cancer: results from the EPICAP study. Oncotarget [Internet]. 2018 May 4 [cited 2019 Feb 15]; Available from: http://www.oncotarget.com/fulltext/25320
  • Lee CH, Akin-Olugbade O, Kirschenbaum A. Overview of Prostate Anatomy, Histology, and Pathology. Endocrinol Metab Clin North Am. 2011 Sep;40(3):565–75.
  • Lloyd T, Hounsome L, Mehay A, Mee S, Verne J, Cooper A. Lifetime risk of being diagnosed with, or dying from, prostate cancer by major ethnic group in England 2008–2010. BMC Med [Internet]. 2015 Dec [cited 2015 Nov 5];13(1). Available from: http://www.biomedcentral.com/1741-7015/13/171
  • Mottet N, Cornford P, Van den Bergh RCN, Briers E, De Santis M, Fanti S, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer [Internet]. European Association of Urology; 2020 [cited 2020 Nov 18]. Available from: https://uroweb.org/wp-content/uploads/EAU-EANM-ESTRO-ESUR-SIOG-Guidelines-on-Prostate-Cancer-2020v4.pdf
  • National Institute for Health and Care Excellence. Lower urinary tract symptoms in men: management. 2010.
  • National Institute for Health and Care Excellence. Prostate cancer: diagnosis and management. NICE guideline 131. 2019.
  • National Institute for Health and Care Excellence. Prostate cancer. NICE Clinical knowledge summary [Internet]. 2017 [cited 2020 Nov 26]. Available from: https://cks.nice.org.uk/topics/prostate-cancer/#!diagnosis
  • National Institute for Health and Care Excellence. Prostatitis (acute): antimicrobial prescribing. NICE guideline 110 [Internet]. 2018 [cited 2019 Jan 3]. Available from: https://www.nice.org.uk/guidance/ng110
  • National Institute for Health and Care Excellence. Suspected cancer: recognition and referral. NICE guideline 12 [Internet]. 2020. Available from: https://www.nice.org.uk/guidance/ng12
  • Office for Health Improvement and Disparities. Prostate specific antigen testing: advice for well men aged 50 and over [Internet]. GOV.UK; 2022 [cited 2022 Jan 27]. Available from: https://www.gov.uk/government/publications/prostate-specific-antigen-testing-description-in-brief
  • Ørsted DD, Bojesen SE. The link between benign prostatic hyperplasia and prostate cancer. Nat Rev Urol. 2012;10(1):49–54.
  • Perez-Cornago A, Appleby PN, Pischon T, Tsilidis KK, Tjønneland A, Olsen A, et al. Tall height and obesity are associated with an increased risk of aggressive prostate cancer: results from the EPIC cohort study. BMC Med [Internet]. 2017 Dec [cited 2017 Dec 1];15(1). Available from: http://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-017-0876-7
  • Prostate Cancer UK. Consensus statements on PSA testing in asymptomatic men in the UK [Internet]. 2016. Available from: www.prostatecanceruk.org/PSAconsensusHP
  • Public Health England. Prostate cancer risk management programme (PCRMP): benefits and risks of PSA testing [Internet]. GOV.UK; 2016. Available from: https://www.gov.uk/government/publications/prostate-cancer-risk-management-programme-psa-test-benefits-and-risks/prostate-cancer-risk-management-programme-pcrmp-benefits-and-risks-of-psa-testing
  • Rees J, Abrahams M, Doble A, Cooper A, the Prostatitis Expert Reference Group (PERG). Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline. BJU Int. 2015 Oct;116(4):509–25.
  • Rees J, Bultitude M, Challacombe B. The management of lower urinary tract symptoms in men. BMJ. 2014 Jun 24;348(1):g3861–g3861.
  • Schenk JM, Kristal AR, Arnold KB, Tangen CM, Neuhouser ML, Lin DW, et al. Association of Symptomatic Benign Prostatic Hyperplasia and Prostate Cancer: Results from the Prostate Cancer Prevention Trial. Am J Epidemiol. 2011;173(12):1419–28.
  • Shoskes DA. The Challenge of Erectile Dysfunction in the Man with Chronic Prostatitis/Chronic Pelvic Pain Syndrome. Curr Urol Rep. 2012 May 13;13(4):263–7.
  • Speakman M, Kirby R, Doyle S, Ioannou C. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) - focus on the UK: Burden of male LUTS suggestive of BPH. BJU Int. 2015 Apr;115(4):508–19.
  • Walsh AL, Considine SW, Thomas AZ, Lynch TH, Manecksha RP. Digital rectal examination in primary care is important for early detection of prostate cancer: a retrospective cohort analysis study. Br J Gen Pract J R Coll Gen Pract. 2014 Dec;64(629):e783-787.
  • World Cancer Research Fund International. Continuous Update Project report: Diet, Nutrition, Physical Activity and Prostate Cancer [Internet]. 2014. Available from: www.wcrf.org/sites/default/files/Prostate-Cancer-2014-Report.pdf
  • Roshna Bhulia, Trainee Advanced Clinical Practitioner
  • Christian Brown, Consultant Urologist
  • Francis Chinegwundoh MBE, Consultant Urological Surgeon
  • Nicola Lancaster, Macmillan Metastatic Prostate Cancer Clinical Nurse Specialist
  • Our Specialist Nurses
  • Our volunteers.